Watanabe S, Kagawa H, Shirai M, Nishioka M
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1635-41.
Ten patients with hepatocellular carcinoma (HCC) received intra-tumoral injection of OK-432 (6 patients), 99.5% ethanol (2 patients) or both (2 patients). Under ultrasonographic control, a PTC needle (22 G) was inserted percutaneously into the tumor and OK-432, which was prepared with a solution of Su-strain Streptococcus pyogenes A3, or 99.5% ethanol was injected. Patients were injected with OK-432 repeatedly at one-to two-week intervals (up to 5 times) for a total duration of 5 to 15 weeks. The degree of skin test reaction for Streptococcus pyogenes was increased in all patients after the treatment. Over 40% tumor regression was noted in 6 out of 9 patients who received intra-tumoral injection of OK-432. Complete regression was noted in one patient. Before treatment, Interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cell activity in peripheral blood lymphocytes decreased in HCC patients. Two of 6 patients showed markedly increased activity of LAK-cells one week after treatment with OK-432. One other patient had moderately increased LAK-cell activity after treatment with OK-432. No increase in LAK-cell activity was seen in 3 patients who received intra-tumoral injection of ethanol. An especially increased response of LAK-cell activity was seen in patients with small-sized HCC (diameter below 5 cm).
10例肝细胞癌（HCC）患者接受了瘤内注射OK - 432（6例）、99.5%乙醇（2例）或两者联合注射（2例）。在超声引导下，经皮将一根22G的经皮肝穿刺针（PTC针）插入肿瘤内，然后注射用化脓性链球菌A3株制备的OK - 432或99.5%乙醇。患者每隔1至2周重复注射OK - 432（最多5次），总疗程为5至15周。治疗后所有患者化脓性链球菌皮肤试验反应程度均增加。在接受瘤内注射OK - 432的9例患者中，6例肿瘤缩小超过40%，1例完全缓解。治疗前，HCC患者外周血淋巴细胞中的白细胞介素-2（IL - 2）和淋巴因子激活的杀伤细胞（LAK）活性降低。6例患者中有2例在接受OK - 432治疗1周后LAK细胞活性显著增加。另1例患者接受OK - 432治疗后LAK细胞活性中度增加。接受瘤内注射乙醇的3例患者LAK细胞活性未见增加。在小尺寸HCC（直径小于5 cm）患者中观察到LAK细胞活性有特别明显的增加。
